• Contact Us

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Coming Soon – Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target
      • Kinase Assays
      • ATPase Assays
      • cGAS Assays
      • Glycosyltransferase Assays
      • Phosphodiesterase Assays
      • Ligase and Synthetase Assay
      • Methyltransferase Assay Kits
      • GTPase Assays
      • GAP Assays
      • GEF Assays
    • Ordering Information
  • Therapeutics
    • Pipeline
    • Scientific Advisory Board
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Residence Time Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
  • Blog
  • MY CART
    No products in cart.

Category: Company

BellBrook Labs Recap of SLAS 2019 in Washington DC.

Tuesday, 29 January 2019 by Bellbrook Labs
SLAS 2019
BellBrook Labs will be exhibiting and have poster presentations at the upcoming SLAS conference. During the meeting, BellBrook will have information available demonstrating a variety of applications for Transcreener HTS tools. Stop by booth #1702 where you can receive your copy of “A Guide to Measuring Drug-Target Residence Times with Biochemical Assays.” We are looking forward
Read more
  • Published in Company, HTS Assays
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer

Tuesday, 22 May 2018 by Bellbrook Labs
Autoimmune Disease News
The National Institutes of General Medical Sciences (NIGMS) recently awarded BellBrook Labs a $1 million phase II Small Business Innovative Research (SBIR) grant to develop new assays to detect cyclic GMP-AMP (cGAMP) levels in biological samples. The assays will be used to discover, develop, and monitor new treatments for autoimmune diseases and cancer by targeting
Transcreener cGAMP cGAS Assay
Read more
  • Published in Company, Emerging Targets, News
No Comments

Enhancing Checkpoint Blockade Immunotherapy: Sensitizing Tumors with HSP90 Inhibitors

Wednesday, 02 May 2018 by Bellbrook Labs
HSP90 Inhibitor Immunotherapy
Checkpoint blockade is turning heads in the oncology community. This form of immunotherapy, which uses anti-PD-1 or anti-CTLA-4 antibodies to coax the immune system into recognizing and attacking cancer cells, has been a game-changer — but only for some patients. Types of cancer for which checkpoint blockade currently cannot presently be used include gastrointestinal tumors
ATPase AssayTranscreener ADP Kinase Assay
Read more
  • Published in Company, HTS Assays
No Comments

Transcreener ADP Assay Aids in Discovery of RIPK2 Inhibitors for Autoinflammation

Wednesday, 17 January 2018 by Bellbrook Labs
When the body responds to a bacterial pathogen, fragments of bacterial peptidoglycan alert a human host to the presence of a microbial invader. A receptor named NOD2 recognizes the peptidoglycans and sounds the alarm, initiating immune responses by causing the production of pro-inflammatory cytokines via NF-κB and MAP kinase pathways 1. In this manner, NOD2
Transcreener ADP Kinase Assay
Read more
  • Published in Company, HTS Assays, News, Products, Success Stories
No Comments

Discovery on Target 2017

Tuesday, 05 September 2017 by Bellbrook Labs
  Here is what you may have missed… Exhibition Learn about our new AptaFluor SAH Methyltransferase Assay Discuss which HTS assays might be a fit for your research Discover how BellBrook Labs’ services can help accelerate your drug discovery program Presentations/Talks Targeting the cGAS-STING Pathway Using a Homogenous, HTS Compatible Transcreener® cGAS Assay Thursday, September
Read more
  • Published in Company, News
No Comments

New Publication: HTS Method for Measuring Drug Residence Time

Tuesday, 25 April 2017 by Bellbrook Labs
View our latest publication, “A High-Throughput Method for Measuring Drug Residence Time Using the Transcreener® ADP2 Assay” in SLAS Discovery. Inhibitor residence times are increasingly being used to prioritize molecules early in lead discovery programs. Current methods for determining residence time are low-throughput or require the synthesis of labeled ligands. Our goal was to create
Assay Development Servicesdrug discovery servicesLead Discovery ServicesResidence TimeTranscreener ADP Kinase AssayTranscreener AMP/GMP AssayTranscreener GDP AssayTranscreener UDP Assay
Read more
  • Published in Company, HTS Assays, News
No Comments

Detecting Rho-GEF Activity Using the Transcreener® GDP Assay

Friday, 24 March 2017 by Bellbrook Labs
Rho GTPases act as molecular switches to regulate the cytoskeletal dynamics underlying cell motility.  Rho GEFs (guanine nucleotide exchange factors) positively regulate Rho GTPases by accelerating GDP dissociation and allowing formation of the active GTPase-GTP complex. Active Rho GTPases typically stimulate cell growth and migration, sometimes triggering tumorigenesis or invasion. Selectively disrupting GEF action using
Assay Development Servicesdrug discovery servicesGEF AssayGTPase AssayLead Discovery ServicesTranscreener GDP Assay
Read more
  • Published in Company, HTS Assays, Products
No Comments

BellBrook Labs Expands Drug Discovery Services Portfolio to Include Lead Discovery Services

Wednesday, 22 February 2017 by Bellbrook Labs
Madison, WI, February 2017 – In response to an increasing demand for characterization and prioritization of compounds downstream of HTS or virtual screening, BellBrook Labs is expanding its Drug Discovery Services to include Lead Discovery in addition to Assay Development.  BellBrook will use its proprietary Transcreener® HTS assay platform to accelerate clients’ hit-to-lead and SAR
Assay Development Servicesdrug discovery servicesLead Discovery Services
Read more
  • Published in Company, News
No Comments

SLAS Conference 2017 Recap

Tuesday, 14 February 2017 by Bellbrook Labs
SLAS Conference 2017 Recap Here is what you may have missed… Discussions at the Exhibit Included The expansion of BellBrooks’s Drug Discovery Services What’s new in the field of HTS sssays How Transcreener® Assays are accelerating drug discovery Current challenges to the field of drug discovery and potential solutions moving forward Posters Presented at the Conference
Read more
  • Published in Company, News
No Comments

What’s New at BellBrook Labs? Find Out at SLAS 2017.

Friday, 20 January 2017 by Bellbrook Labs
SLAS 2017 Meeting February 4th-8th Walter E. Washington Convention Center Washington, DC Exhibition Visit Booth #245 to: Learn about the expansion of BellBrooks’s Drug Discovery Services Discuss which HTS assays might be a fit for your research Discover how Transcreener® Assays are accelerating drug discovery Poster Presentations A Homogenous, Universal Enzymatic Assay for Histone Methyltransferases Based
Read more
  • Published in Company, News
No Comments
  • 1
  • 2

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2019

    BellBrook Labs Recap of SLAS 2019 in Washington DC.

    BellBrook Labs will be exhibiting and have post...
  • What is a kinase assay

    How Does a Biochemical Kinase Assay Work?

    A kinase assay works by simply measuring the ac...
  • Lupus NIK Inhibitor

    Transcreener ADP Assay Enables Evaluation of NIK Inhibitors in Lupus Drug Discovery

      Systemic lupus erythematosus (SLE), or l...
  • Histone Methylation PRMT4

    Sensitive Methyltransferase Assay Proves Successful with PRMT4

    Histone methyltransferases (HMTs) play a critic...
  • Acetyl CoA Carboxylase Inhibitors

    Acetyl-CoA Carboxylase Inhibitors: Transcreener ADP Assay Powers Drug Detection Strategy

    The impact of Acetyl-CoA carboxylases (ACCs) on...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA

(608) 443-2400

info@bellbrooklabs.com

Powered by Digital Fitness | Copyright © 2018 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP